Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
04/10/2020 05:00 PM EDT The piece raises several important concerns regarding COVID-19 for specific vulnerable populations. |
NIDA Director outlines potential risks to people who smoke and use drugs during COVID-19 pandemic
Shamp, LeStrange & Jansen at "Divine Interruptions"
|
Google Alert - cannabidiol for epilepsy
cannabidiol for epilepsy | |||||
NEWS | |||||
FDA Grants GW Pharmaceuticals Priority Review For Cannabidiol Drug In Seizure Condition Epidiolex oral solution, CV, has already been authorized for treating seizures connected with two rare forms of childhood-onset epilepsy, Lennox- ...
| |||||
Cannabidiol as an Adjunctive Therapy for Patients With Treatment-Resistant Dravet Syndrome Cannabidiol daily doses of 10 or 20 mg/kg can be a safe and effective adjunct treatment to reduce seizure in patients with highly resistant Dravet ...
| |||||
See more results | Edit this alert |
You have received this email because you have subscribed to Google Alerts. |
Receive this alert as RSS feed |
Send Feedback |
Jodie Hughes: "Call to Me and I Will Answer"
If you cannot read this message correctly, please click here
|
Single mutation leads to big effects in autism-related gene
Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
04/02/2020 11:00 AM EDT NIH study provides insight into one mechanism underlying the higher prevalence of males in some cases of autism. Update Your E-mail Address | Add Subscriptions | Unsubscribe If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health.
|
Bringing Needed Structure to COVID-19 Drug Development
See how new molecular mapping work may lead to targeted drugs for this major public health challenge |
Update Your E-mail Address | Add Subscriptions | Unsubscribe If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health.
|
NIH-funded research leads to pediatric labeling updates for doxycycline, clindamycin and caffeine citrate
Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
04/02/2020 09:00 AM EDT Labels now include better information for healthcare providers on recommended usage and dosage in pediatric populations. Update Your E-mail Address | Add Subscriptions | Unsubscribe If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health.
|
2020 Health Report: #1 Contaminated Food Discovery
|
-
P A I D A D V E R T I S E M E N T Itching THIS Part of Your Body Is a Sign of Alzheimer's ...
-
You may qualify for a clinical trial to test CBD GS Handbook 16-17 August 2016 I Graduate School 2016-2017 HANDBOOK for Graduate Studen...
-
P A I D A D V E R T I S E M E N T Urgent news about Metformin Doctors ...